pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute for clinical programs — 406 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
George Institute for projects
406 ClinicalTrials.gov programs sponsored by George Institute for.
George Institute for has 406 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
C20-48
The George Institute
Pneumonia
1 trial -
CAR123 T cell treatment of relapsed/refractory hematologic malignancies.
The George Institute
Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.
1 trial -
CBR-CMR316-3001
The George Institute
Idiopathic Pulmonary Fibrosis
1 trial -
CCHF-NP-1
The George Institute
Crimean Congo Hemorrhagic Fever
1 trial -
CD5CAR-NK cells for refractory invasive mold disease
The George Institute
refractory invasive mold disease
1 trial -
CEREAL-IPC 2016-010
The George Institute
Acute leukemia and myelodysplastic syndromes
1 trial -
CSET N°2021/3339
The George Institute
Neoadjuvant therapy in locally-advanced rectal cancer
1 trial -
DELAY
The George Institute
Lynch Syndrome
1 trial -
DS101-CT-01
The George Institute
Diabetic retinopathy.
1 trial -
DS101-CT-01
The George Institute
Diabetic retinopathy.
1 trial -
First in human study of the infusion of ARI00...
The George Institute
Relapsed/refractory B-cell aggressive lymphoma
1 trial -
IC 2018-06
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
IC 2022-10
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
INSIGHT
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial -
IOR-BMS-IST-002
The George Institute
Non-small cell lung cancer (NSCLC)
1 trial -
KIH24001
The George Institute
Alzheimer´s disease
1 trial -
NeoTISLEGA - A phase Ib trial evaluating the...
The George Institute
resectable esophagogastric adenocarcinoma
1 trial -
Phase I-Ib clinical trial of safety and immun... for graft-versus-host disease
The George Institute
graft-versus-host disease
1 trial -
Phase I-Ib clinical trial of safety and immun... for graft-versus-host disease
The George Institute
graft-versus-host disease
1 trial -
S005183-297
The George Institute
No medical condition.
1 trial -
S005183-303
The George Institute
No medical condition.
1 trial -
S005190-203
The George Institute
No medical condition.
1 trial -
S005190-204
The George Institute
No medical condition.
1 trial -
S005190-205
The George Institute
No medical condition.
1 trial -
S005190-206
The George Institute
No medical condicion.
1 trial -
S005190-213
The George Institute
No medical condicion.
1 trial -
S095031-218
The George Institute
Newly diagnosed and/or previously treated IDH1-mutated malignancies
1 trial -
S221237-176
The George Institute
No medical condition
1 trial -
SUITH
The George Institute
Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments
1 trial -
The TILS001 trial
The George Institute
advanced or metastasic triple-negative breast cancer
1 trial -
UHKT-CAR19-01
The George Institute
Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma
1 trial -
VHIO20001
The George Institute
Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors
1 trial -
VHIO20002
The George Institute
Refractory metastatic Her2 positive breast cancer
1 trial -
VHIO24001
The George Institute
Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
1 trial -
VHIO24001
The George Institute
Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)
1 trial -
-
The George Institute
Acute lower Respiratory Tract Infection or acute rhinosinusitis
1 trial -
2024/3873 CABOLD
The George Institute
Renal carcinoma
1 trial -
AB.OH.2025
The George Institute
Infectious diseases
1 trial -
ACETYLSALICYLIC ACID
The George Institute
Obstetrics – Preeclampsia
1 trial -
ADIPGEN
The George Institute
Knee Osteoarthritis
1 trial -
ALLERDOG
The George Institute
Allergic rhinitis due to dog allergy
1 trial -
AMOXICILINA NORMON 1000 mg Comprimidos EFG
The George Institute
Infective endocarditis
1 trial -
ANGELO
The George Institute
Obesity
1 trial -
Alirocumab, Placebo product for REGN727
The George Institute
Cardiac allograft vaculopathy in recent heart transplant recipients
1 trial -
Amiodarone hydrochloride 200 mg tablets
The George Institute
Persistent atrial fibrillation
1 trial -
Avian_inf_vacc_THL20
The George Institute
Avian influenza and seasonal influenza
1 trial -
BIMERVAX LP.8.1 emulsion for injection COVID... for COVID-19 infection
The George Institute
COVID-19 infection
1 trial -
BUDESONIDE
The George Institute
Chronic obstructive pulmonary disease (COPD)
1 trial
Frequently asked questions
How many clinical projects does George Institute for have?
406 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.